Curium received FDA approval for its “radioligand equivalent” to Novartis’s Lutathera, marking the first generic radioligand cleared in the U.S. The decision sets up regulatory and competitive pressure in a radioligand market where Novartis had established early leadership. The approval creates a new pathway for radiopharmaceutical substitution, which may affect pricing, access, and how clinicians select imaging and therapy options in eligible patient populations. For manufacturers, the step reinforces that radioligand products can be evaluated through an equivalence framework. The broader impact is likely to be felt in the radioligand pipeline and commercial strategies of both originators and emerging competitors seeking to expand access through follow-on products.